Innovative Cancer Therapeutics

A special issue of Bioengineering (ISSN 2306-5354). This special issue belongs to the section "Biomedical Engineering and Biomaterials".

Deadline for manuscript submissions: 15 July 2024 | Viewed by 567

Special Issue Editors

E-Mail Website
Guest Editor
Mayo Clinic Arizona, Scottsdale, AZ, USA
Interests: molecular biology; neoplasms; therapeutics; genomics; genes and cell therapy; population genetics; multiomics; cancer research

E-Mail Website
Guest Editor
Department of Surgical Gastroenterology, Sanjay Gandhi Post Graduate Institute of Medical Sciences, Raebareli Road, Lucknow 226014, India
Interests: abdominal surgery; gastrointestinal surgery; pancreatic resection; colorectal surgery; cancer research; therapeutics; genomics

Special Issue Information

Dear Colleagues,

Cancer is the leading cause of mortality worldwide. The development of efficacious drugs is highly challenging in cancer for various reasons including genetic heterogeneity. Current ongoing research on cancer therapy has turned out to be promising and has revolutionized the way cancer used to be treated before. The discovery of various cancer-related innovative therapies, like stem-cell-based therapies, nanoparticle-carrier-based therapies and immunotherapy have tackled the concerns of conventional cancer treatment therapy (chemo and/or radiotherapy), treatment outcome, treatment-related side effects, drug specificity, drug metabolism and drug toxicity, etc., to a great extent. However, every treatment protocol has its own advantages and disadvantages linked with various clinical characteristics of tumor as well as inter/intra tumoral heterogeneity. Therefore, we still need more research targeted towards innovative cancer therapeutics that can lead to improved prognosis and survival with no/less treatment-related complications with a strategy to convert a terminal disease into a more controllable condition.

Innovative cancer therapeutics is a peer-reviewed journal that will focus on high-quality research articles focusing on various aspects of emerging cancer therapeutics that are currently being researched with an aim to provide information and advanced knowledge to the researchers working in this area. Additionally, we sincerely appreciate and acknowledge insights and discussions from oncology professionals globally. The main scope of this journal issue is to provide an interdisciplinary platform for researchers from all over the world to publish quality research as well as review articles covering the broad aspects of cancer therapeutics including basic, clinical research, translational research, technological advancements, precision diagnosis, and treatment of cancer.

Dr. Ashok Kumar
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Bioengineering is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.


  • cancer
  • immunotherapy
  • CAR T cells
  • neoplasm
  • stem cell therapy
  • chemotherapy
  • radiotherapy
  • monoclonal antibody

Published Papers

This special issue is now open for submission.
Back to TopTop